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Introduction
My colleagues and I have recently reported several lines of
evidence for a potential role of immunological intervention in
the pathogenic process of osteoarthritis (OA). In particular,
we have focused on the role of activated T cells [1] after an
immunological response to the cartilage component [2–4]
with activation by chemokines [5,6]. The background of this
concept comes from a pathological feature of OA synovium.
Although OA is generally accepted as one of the common-
est degenerative joint disorders caused by biomechanical
stress or aging, instances of inflammatory features such as
synovial effusion or swelling of affected joints have been
reported. The accumulation of mononuclear cells in synovial
fluid, an increasing concentration of immunoglobulin and
pathological findings of OA synovial tissue such as hyper-
plasia of synovial lining cells and infiltration of inflammatory
cells into the sublining layer  strongly suggest chronic
inflammatory features of OA. These findings resemble the
early stage of rheumatoid arthritis [7–9]. We were therefore
interested in the immune response to cartilage components
such as cartilage intermediate layer protein (CILP) and
YKL39 [10,11]. In particular, endogenous articular cartilage
components have been found to provide a rich source of
antigenic determinants in OA.
We previously detected CD3 T cells in the synovium
tissue and CD4+CD8+ cells in the sublining layer in OA.
Moreover, the number of interferon-γ-bearing T cells was
fivefold that of IL-4-positive cells. In addition, we identified
clonal diversity in the infiltrated T cells [1]. These findings
of oligoclonal T cell expansion in OA synovium and the
presence of T cell aggregates undergoing in situ activa-
tion in a rather specific manner indicate that a Th1 cell-
mediated specific immune response might be taking place
in OA synovium, driven by local antigens.
Why should T cells have a potential role in the pathogenic
process of cartilage destruction in OA? Current work sug-
gests that extracellular matrix-filling material hyaluronan
can modulate the function of antigen-presenting cells in
monocytes. Recent studies show that dendritic cells and
T cells constitutionally express genes involved in hyaluro-
nan synthesis (HAS1 and  HAS3) and encoding
hyaluronidase, Hyal3 [12]. After the secretion of hyaluron-
degrading enzymes, dendritic cells and T cells need to
detach from the extracellular matrix to migrate from or to
lymph nodes. Either way, an involvement of the T cell acti-
vation process in joints is strongly associated with
turnover of extracellular hyaluronan.
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Abstract
Whatever the initiating factor of osteoarthritis (OA), the process ultimately unmasks the immunogenic
determinants of chondrocytes, proteoglycans and collagens, which then triggers autoimmune
reactions. Although the precise mechanism of the immune responses in the pathogenesis of OA
requires further investigation, here I postulate that the presence of autoimmunity to cartilage
components has an important role in the process of cartilage degradation in OA. Current studies
strongly suggest that a immunoregulatory therapeutic strategy should be established.
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In conclusion, I would like to emphasize that examining the
potential role of T cells and autoantibody against cartilage
components in OA has been instrumental in developing
not only new insights into the pathogenesis of OA but also
novel strategies for the treatment of OA, such as the appli-
cation of an immunomodulative agent.
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